LL-37
Also known as: Cathelicidin, CAP-18
A human cathelicidin antimicrobial peptide with broad-spectrum activity against bacteria, viruses, and fungi. Also modulates immune response.
Mechanism of Action
Disrupts microbial membranes, neutralizes bacterial endotoxins (LPS), promotes wound healing, modulates TLR signaling, and recruits immune cells.
Dosing Protocol
50-100 mcg subcutaneous daily. Often cycled 4-6 weeks.
Open peptide calculatorReconstitution
5mg vial + 2mL BAC water = 2500 mcg/mL.
Storage
Lyophilized: -20°C. Reconstituted: 2-8°C.
Side Effects
- ●Injection site redness
- ●Mild inflammatory response
Key Research Findings
- ●Broad-spectrum antimicrobial activity demonstrated in vitro
- ●Anti-biofilm properties against MRSA and Pseudomonas
- ●Immune modulation in chronic infection models
Latest Verified Lab Report
No lab reports available for LL-37 yet.
Community-funded testing results will appear here.
Vendor Trust Leaderboard
Trust leaderboard coming soon.
Vendor rankings based on verified lab test results.
Research Use Only
This information is provided for educational and research purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before using any research compounds.